AstraZeneca’s asthma drug fails end-stage trial in COPD
HQ Team September 17, 2025: AstraZeneca’s asthma drug Fasenra (benralizumab) has  failed to meet its primary goal in a Phase III trial for.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team September 17, 2025: AstraZeneca’s asthma drug Fasenra (benralizumab) has  failed to meet its primary goal in a Phase III trial for.
HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.
Bharti Jayshankar November 29, 2024: Around half a billion people live with asthma and chronic obstructive pulmonary disease (COPD). The Global Burden of.
HQ Team November 15, 2024:Allergies are a source of great social and physical impairment for people suffering from them. Treatments are long-drawn, expensive.
The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in.
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.
HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.
HQ Team May 4, 2024: A new research says that nitrogen dioxide gas (NO2) emitted by gas and propane stoves is likely to.
Israel’s Teva Pharmaceutical Industries, and US-based Launch Therapeutics, have joined hands to speed up the development of an experimental asthma drug.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com